Microsoft word - cvjan06.doc
Page 1/11 D. Paul, D.O., Ph.D.
DEV PAUL-CURRICULUM VITAE
Office Address & Telephone
Office Phone: (303) 321-0302Fax: (303) 321-9296
D.O./Ph.D. Pathology, Medical Scientist Training Program (MSTP) Scholarship,
Michigan State University, College of OsteopathicMedicine, E. Lansing, MI. 1984-1991.
B.A./B.S. Biology, Summa Cum Laude (GPA 3.84)
University of Bridgeport, Bridgeport, CT. 1979-1983.
High School Diploma (Early Admission to the University of Bridgeport).
Stratford High School, Stratford, CT. 1980.
Fellowship Medical Oncology
National Cancer Institute,
National Institutes of Health, Bethesda, MD.
July 1995-June 1998.
Residency Internal MedicineUniversity of Wisconsin Hospital and Clinics, Madison, WI.
Rotating InternshipLansing General Hospital, Lansing, MI.
Diplomate, Medical Oncology, American Board of Internal Medicine (ABIM),
Diplomate, American Board of Internal Medicine (ABIM), August 1995.
Recertified November 16, 2005.
Diplomate of the National Board of Osteopathic Medical Examiners, July 1992.
Page 2/11 D. Paul, D.O., Ph.D.
Current Position and Clinical Practice Interests and Experience
Private practice, specializing in breast cancer in Denver, CO.
Rose Medical Center, Denver CO.
Presbyterian-Saint Luke’s Hospital, Denver, CO.
Saint Joseph’s Hospital, Denver, CO.
Sky Ridge Medical Center, Lone Tree, CO.
Honors and Awards
2001-Colorado Cancer Research Program (CCRP), Highest New Patient
Enrollment to CCRP Clinical Trials, FYE May 2001
2001-Colorado Cancer Research Program (CCRP), The Robert F. Berris Award
for Highest Accrual to Clinical Trials FYE May 2001
1992-Geropsych Award, Lansing General Hospital, Lansing MI.
1991-Medical Access Award, College of Osteopathic Medicine,
Michigan State University, E. Lansing, MI.
1984-1991-Medical Scientist Training Program Scholarship/Award,
College of Osteopathic Medicine, Michigan State University,E. Lansing, MI.
1982-Who's Who Among American College Students.
1981-Phi Kappa Phi, University of Bridgeport, Bridgeport, CT.
1979-1983-Full 4 year academic undergraduate scholarship,
University of Bridgeport, Bridgeport CT.
1979-Early admission (junior year of high school) to the University of
1979-National Honor Society, Stratford High School, Stratford, CT.
Lieutenant Commander, Medical Officer, Reserve Corps, United States Public
Health Service, National Naval Medical Center and National Cancer Institute,
National Institutes of Health, Bethesda, MD. September, 1995-September,
Page 3/11 D. Paul, D.O., Ph.D.
Clinical Preceptor, Kirksville College of Osteopathic Medicine, since 2002.
Adjunct Clinical Faculty, Touro University College of Osteopathic Medicine, since2002.
Ongoing teaching of and supervising medical residents, interns medical studentsand nurse practitioner students.
Teaching Assistant, Medical Histology, College of Osteopathic Medicine,
Michigan State University, E. Lansing, MI. 1990.
American Association for the Advancement of Science
American College of Physicians
American Medical Association
American Osteopathic Association
American Society of Clinical Oncologists
Colorado Medical Society
Denver Medical Society
Rocky Mountain Oncology Society
Committees and Meetings
Genomics in Breast Cancer Oncotype Dx Breast Cancer Assay Summit.
Consultant. The Ritz Carlton, Phoenix, Arizona, 01/15/05.
27th Annual San Antonio Breast Cancer Symposium, December 8-11, 2004. SanAntonio Convention Center, San Antonio, TX.
26th Annual San Antonio Breast Cancer Symposium, December 3-6, 2003. SanAntonio Convention Center, San Antonio, TX.
Summit; Oncotype Dx Breast Cancer Assay. Consultant. The Sofitel, ChicagoWater Tower Hotel, Chicago, Illinois, 05/06/04 through 05/08/04.
Member North Central Cancer Treatment Group (NCCPT) 2004.
Taxotere (docetaxel) Early Stage Breast Cancer Consultants Meeting.
Restaurant Kevin Taylor, Hotel Teatro, Denver CO. August 14, 2003.
Breast Cancer Committee Member, US Oncology, since August 2003.
US Oncology Clinical Research Meeting Focus on US Oncology Clinical Trial 01-062 (Adjuvant Breast Cancer: Adriamycin and Cytoxan X 4 followed by Taxoterex 4 +/- Xeloda). May 17, 2003. Omni Mandalay Hotel, Dallas, TX.
Page 4/11 D. Paul, D.O., Ph.D.
Chairman Cancer Committee, Rose Medical Center, Denver Colorado. January2003 – January 2005.
Medical Advisor, Rocky Mountain Cancer Centers Safety Committee, January2003 – present.
25th Annual San Antonio Breast Cancer Symposium, December 11-14, 2002.
San Antonio Convention Center, San Antonio, TX.
Southwestern Taxotere Advisory Board Meeting, August 16-18, 2002, TheVenetian Hotel, Resort & Casino, Las Vegas, NV.
Teaching Course in Mammography : Advanced Diagnostic Course withScreening. Laszlo Tabar, M.D., Mammography Education, Inc. January 24-27,2002. Rancho Las Palmas Marriott Resort & Spa, Rancho Mirage, CA.
24th Annual San Antonio Breast Cancer Symposium, December 10-13, 2001.
The Marriott Rivercenter Hotel, San Antonio, TX.
Faslodex Consultancy Meeting, November 11, 2001. The Westin Tabor Center,Denver, CO.
Arimidex Regional Advisory Board, September 7-9, 2001. Cheyenne MountainConference Resort, Colorado Springs, CO.
Taxotere (docetaxel) Advisory Board, February 9-11, 2001. Keystone Center,Keystone, CO.
23rd Annual San Antonio Breast Cancer Symposium, December 9-12, 2000.
The Marriott Rivercenter Hotel, San Antonio, Tx.
Taxotere (docetaxel) Advisory Board, February 19-20, 2000. Cordelera Spa,Vail, CO.
22nd Annual San Antonio Breast Cancer Symposium, December 8-11, 1999. TheMarriott Rivercenter Hotel, San Antonio, Tx.
Neutrexin (trimetrexate) Regional Advisory Board, November 19-20, 1999. TheBroadmoor Hotel, Colorado Springs, CO.
“Y-ME” Breast Cancer Hopeline, Rocky Mountain Breast Cancer Network.
Medical Advisor since 1999-2004.
Teaching Course in Mammography, Laszlo Tabar, M.D., MammographyEducation, Inc. August 11-14, 1999. The Drake Hotel, Chicago, IL.
Page 5/11 D. Paul, D.O., Ph.D.
Taxotere (docetaxel) Local Advisory Board Meeting, October 3, 1998. TheBroadmoor Hotel, Colorado Springs, CO.
Cancer Committee, Rose Hospital, Denver, CO, since 1998.
Colorado Cancer Research Program (CCRP) Investigator since 1998
Core Course in Clinical Research, October 1997-June 1998. National Institutesof Health Clinical Center, Bethesda, MD.
Journals for which Manuscripts were Critically Reviewed
International Journal of Cancer
Journal of Hyperthermia
“Chemotherapy for Breast Cancer: What’s Best and How DO You Decide. Rocky
Mountain Surgeons Consortium, Sonnenalp Resort, Vail, CO. February 5, 2006.
“Breast Cancer Treatment Landscape and the Importance of Clinical Trials.” Y-Me National Breast Cancer Organization, Holiday Inn Select, Denver, CO.
November 20, 2003.
“Pain: Traditional and Non-traditional Remedies.” Presented with BonnieWilenski. 22nd Annual Day of Caring for Breast Cancer Awareness, DenverMerchandise Mart, Denver, CO.
May 3, 2003
”Your Turn: Meet the Medical Experts.” 21st Annual Day of Caring for BreastCancer Awareness, Denver Merchandise Mart, Denver CO.
May 11, 2002
“Case Studies in Treatment: Tumor Board.” 21st Annual Day of Caring for BreastCancer Awareness, Denver Merchandise Mart, Denver CO.
May 11, 2002
“Clinical Trials: The Future of Treatment (An Introduction to Breast CancerClinical Trials).” 21st Annual Day of Caring for Breast Cancer Awareness, DenverMerchandise Mart, Denver CO. May 11, 2002
“Breast Cancer: Risk Factors and Risk Reduction.” Longmont United Hospital,Longmont CO.
May 1, 2002
Page 6/11 D. Paul, D.O., Ph.D.
“Meet the Experts” 20TH Annual Day of Caring for Breast Cancer Awareness,Denver Merchandise Mart, Denver CO.
May 12, 2001
“An Introduction to Breast Cancer Clinical Trials” 20TH Annual Day of Caring forBreast Cancer Awareness, Denver Merchandise Mart, Denver CO.
May 12, 2001
“Breast Cancer Risk Factors and Prevention” Rose Hospital Grand Rounds,Denver, CO.
October 3, 2000
“Breast Cancer Prevention: Trial Results.” Denver Metro Oncology NursingSociety. Tante Louise Restaurant, Denver CO.
June 20, 2000
“Adjuvant Chemotherapy for Breast Cancer” 19th Annual Day of Caring forBreast Cancer Awareness, Colorado Convention Center, Denver, CO.
May 6, 2000
“Breast Cancer Prevention: Trial Results.” Nurse Practitioner’s Society,Doubletree Hotel Colorado Springs, CO.
April 19, 2000
“Breast Cancer Prevention: Trial Results.” Breast Cancer Prevention:Incorporating New Data into Clinical Practice. Colorado Cancer ResearchProgram, Ptarmingan Country Club, Fort Collins, CO.
October 28, 1999
“Current Issues in Breast Cancer.” St. Josephs Hospital, Denver CO.
October 25, 1999
“Melanoma in the Rockies: A Multidisciplinary Approach, Adjuvant Therapy.”Also Program Coordinator. The Brown Palace Hotel, Denver, CO.
July 20, 1999
“The STAR Trial (Study of Tamoxifen and Raloxifene): Breast CancerChemoprevention.” Presbyterian-St. Lukes Hospital, Denver CO.
May 25, 1999
“Cancer Imaging.” Denver Society of Radiologic Technologists, Presbyterian-St.
Lukes Hospital, Denver CO.
“Cancer Screening.” Presbyterian-St. Lukes Hospital, Denver CO.
Page 7/11 D. Paul, D.O., Ph.D.
"Construction of an Adeno-Associated Viral Vector for Interleukin-12 MediatedGene Therapy." Department of Experimental Transplantation and Immunology,Medicine Branch, National Cancer Institute, NIH, Bethesda, MD.
April 23, 1998
"Construction of an Adeno-Associated Viral Vector for Interleukin-12 MediatedGene Therapy." H. Lee Moffitt Cancer Center, University of South Florida,Tampa, FL.
December 19, 1997
"Discoveries in Gene Therapy and the Cancer Patient." 4th Annual CancerUpdate: Management & Treatment. Michigan Capitol Medical Center, E.
April 4, 1997
"Construction of an Adeno-Associated Viral Vector for Interleukin-12 MediatedGene Therapy of Breast Cancer." Medical Scientist Training Program, MichiganState University, E. Lansing, MI.
April 3, 1997
"Gene Therapy Strategies for Human Cancer."National Cancer Institute-Navy, Bethesda MD.
May 23, 1996
"Current Issues in Breast Cancer."University of Wisconsin Hospital and Clinics, Madison WI.
December 6, 1994
"Prostate Cancer: Epidemiology, Markers, and the Molecule of the Year (P53)."University of Wisconsin Hospital and Clinics, Madison WI.
February 15, 1994
Medical Scientist Training Program Annual Forum-Presenter, Michigan StateUniversity, E. Lansing, MI.
Research Interests and Experience
Local Principal Investigator: US Oncology 04111 Phase II Study of Doxil and
Carboplatin, plus Herceptin in Her 2+ Patients, in Metastatic Breast Cancer
Page 8/11 D. Paul, D.O., Ph.D.
Principal Investigator: US Oncology 05079 A Phase II Study of Lapatinib forBrain Metastases in Subjects with ErbB2-Positive Breast Cancer FollowingTrastuzumab-based Systemic Therapy and Cranial Radiotherapy. 2005.
Principal Investigator: US Oncology A Phase II open label study of E7389(halichondrin B analog) in patients with advanced/metastatic breast cancerpreviously treated with chemotherapy including an anthracycline and a taxane.
Local Principal Investigator: US Oncology 03069 protocol: E7070-A001-211,Eisai Medical Research, Inc. An open label phase II study of E7070 in metastaticbreast cancer patients previously treated with an anthracycline, Taxane, andcapecitabine (or fluoropyrimidine). 2005.
Co –Principle Investigator. US Oncology 02099 protocol. Phase II trial ofgemcitabine plus carboplatin (plus Trastuzumab in HER-2 positive patients) inmetastatic breast cancer patients. PI: Loesch D. 2004-2005.
Medical Oncology Consultant: 1R1 AGO 22551-01 A1: Chemotherapy oncognition in older breast cancer patients. Principal investigator TerrySimoneau,Ph.D., Sub Investigator Jim Grigsby, Ph.D. Jan 2005- present.
Principal Investigator: US Oncology 04036 protocol. A randomized doubleblinded, placebo-controlled study to evaluation AMG 162 in the treatment of boneloss and subjects undergoing aromatase inhibitor therapy for non-metastaticbreast cancer (20040135). July 2004-May 2005.
Principal Investigator: Multicenter open label phase IV study of Pegfilgrastimadministered in the first and subsequent cycles of myelosuppressivechemotherapy. Amgen protocol 20030218. from 06/29/04 through 06/29/05.
Principle Investigator.UFT (Uracil + Tegafur) and Leucovorin in Stage IV BreastCancer. B98-1310, Bristol Myers Squibb through the Colorado CancerResearch Program (CCRP). August 1999.
Co-investigator on two phase I gene therapy clinical trials (93-C-0208 and 96-C-0007) designed to study retroviral mediated transfer of the human multidrugresistance gene (MDR1) in patients with metastatic breast cancer. Also co-investigator on a phase I bispecific anti-HER2/neu cancer trial (95-C-0023).
Principal investigator for all 3 trials is Kenneth H. Cowan, M.D./Ph.D., Chief,Breast Cancer Section, National Cancer Institute, NIH, Bethesda, Maryland.
Extensive experience with all aspects of delivering experimental cancer therapyprotocols (phase I and II clinical trials), ranging from patient accrual to resolvingvarious protocol issues during and after the course of therapy. (July 1995-present)
Page 9/11 D. Paul, D.O., Ph.D.
Cancer Gene Therapy Studies: Construction of an adeno-associated viral vectorfor interleukin-12 mediated gene therapy of breast cancer, for ultimate use in ahuman anti-cancer gene therapy trial. This work is being performed under thedirection of Kenneth H. Cowan, M.D./Ph.D., Chief, Breast Cancer Section,National Cancer Institute, NIH, Bethesda , Maryland. (July 1996-present)
Phase I study of whole body hyperthermia and melphalan in patients with cancer.
Patient screening for the protocol as well as basic cytokine work in thelaboratory. Under the direction of H. Ian Robins, M.D./Ph.D., Medical OncologySection, University of Wisconsin Hospital and Clinics, Madison, WI. (1993-1995)
Ph.D. Pathology (Medical Scientist Training Program): Basic molecular biologyresearch in the fields of oncogenesis and neuro-carcinogenesis. Dissertationtitle: "Characterization of Single-Stranded DNA Binding Proteins in Rat GlialNuclei." Under the direction of Keiji Marushige, Ph.D. and Adalbert Koestner,DVM, Ph.D., Pathology Department, Michigan State University, East Lansing, MI.
Carson C, Mason F, Lasker-Hertz S, Stanfill-Edens T, Schwartzberg B, Paul D.
Wisner P. An Informational Guide to Breast Cancer. Columbia HCA/CancerCare, Nashville, TN July 2005.
Carson, C., Lasker-Hertz, S., Paul, D
., Schwartzberg, B. et al.
Guide to Breast Cancer (1st revision). Columbia HCA/Cancer Care, Nashville,
TN April 2002.
Neese, P. and Paul, D.
Breast Cancer (Book Chapter), in Oncology Nursing
Secrets (Secrets Series), by R. Gates and R. Fink (Eds).Second edition, 2001.
Qazilbash, M.H., Song, K., Xu, H., Sinha, B.K., Liu, J., and Cowan, K.H.
Construction of a recombinant adeno-associated virus (rAAV) vector expressing
murine interleukin-12 (IL-12). Cancer Gene Therapy
2000 7(2): 308-15.
Carson, C., Lasker-Hertz, S., Paul, D.
, Schwartzberg, B. et al.
Guide to Breast Cancer. Columbia HCA/Cancer Care, Nashville, TN April 2000.
Schneider, E., Paul, D.,
Ivy, P., Cowan KH. Multidrug resistance. Cancer
Chemotherapy and Biological Response Modifiers 1999 18
Page 10/11 D. Paul, D.O., Ph.D.
, Cowan KH. Drug Resistance in Breast Cancer, in Breast Cancer
part of the Contemporary Cancer Research
series. Ed. Anne Bowcock, 1999
pp.481-517. (Book Chapter).
Hoshino T, Jiang Y-Z, Dunn D, Paul D
, Qazilbash M, Cowan K, Wang J, Barrett
J, Liu J. Transfection of interleukin-12 cDNAs into tumor cells induces cytotoxic
immune responses against native tumor: implications for tumor vaccination.Cancer Gene Therapy 1998 5(3): 150-157.
Robins HI, Rushing D., Kutz M., Tiggelaar CL, Paul D
, Spriggs D, Kraemer C,
Gillis W, Feierabend C, Arzoomanian RZ, Longo W, Alberti D, d'Oleire F, Qu RP,
Wilding G, Stewart JA. Phase I clinical trial of melphalan and 41.8 degrees C
whole-body hyperthermia in cancer patients. J Clin Oncol 1997 Jan; 15(1):158-
Robins HI, Kutz M, Wiedemann GJ, Katschinski DM, Paul D
, Grosen E,
Tiggelaar CL, Spriggs D, Gillis W, d'Oleire F. Cytokine induction by 41.8 C whole
body hyperthermia. Cancer Letters 1995 Nov 6; 97(2):195-201.
and Marushige K. Characterization of single-stranded DNA binding
proteins in rat glial-enriched nuclei. Experimental and Molecular Pathology 1994;
. Characterization of Single-Stranded DNA Binding Proteins in Rat Glial
Nuclei. Ph.D. Dissertation, May 1991, Pathology Department, Michigan State
University, East Lansing, MI.
and Gulick P. Mycobacterium marinum
skin infections: Two case
reports. The Journal of Family Practice 1993; 36(3):336-338.
 Impact of Oncotype DX on decision making in breast cancer clinical
practice. Oratz R, Paul D
, Cohn A, Sedlacek S. 28th Annual San Antonio Breast
Cancer Symposium December 8-11, 2005 (Abstract and Poster).
 Phase II trial of gemcitabine plus carboplatin (plus trastuzumab in HER2+
patients) in metastatic breast cancer patients. Loesch DM, Asmar L, McIntyre
KJ, Doane LL, McKittrick RJ, Monticelli MA, Paul D
, Vukelja SJ, Zhan F, Boehm
KA, O'Shaughnessy J. 28th Annual San Antonio Breast Cancer Symposium
December 8-11, 2005 (Abstract and Poster).
Mullineaux L, Oratz R, Paul D
, Sedlacek S. Demographics of BRCA1/BRCA2
mutations in Colorado. Poster presentation/Abstract Lynne Cohen Foundation
Symposium, New York University School of Medicine, New York City, New York,
Page 11/11 D. Paul, D.O., Ph.D.
Duncan AJ, Paul D
, Sedlacek SM, Holmes FA, Vukelja Sj, Wilks ST,
O’Shaughnessy JA. No difference in menopausal symptoms and severity of hot
flashes (HF’s) comparing combined hormone replacement therapy (HRT) plus
tamoxifen (Tam) to tamoxifen alone in peri- or postmenopausal women at high
risk for developing breast cancer. 25th Annual San Antonio Breast Cancer
Symposium, San Antonio Convention Center, San Antonio, Texas, December
Schwartzberg B, Goates J, Levy J, Moore J, Paul D
, Sedlacek S. Sentinel lymph
node biopsy in breast cancer patients enrolled in the NSABP B-27 neoadjuvant
chemotherapy clinical trial. 2nd International Sentinel Node Congress. Accepted
, Qazilbash MH, Seth P, Liu J, Cowan KH. Construction of a recombinant
adeno-associated virus (rAAV) vector for interleukin-12 (IL-12) mediated cancer
gene therapy. Abstract/Poster Presentation, AACR (American Association for
Cancer Research) Annual Meeting
March 31, 1998, New Orleans, LA.
Qazilbash MH, Xiao X, Paul D
, Seth P, Cowan KH, Walsh CE. Anti-tumor
activity of a recombinant adeno-associated virus vector expressing wild-type p53in vivo. Journal of Investigative Medicine 1997, April.
CHAPTER 2: Ontario’s Telehealth system: A novel syndromic surveillance system 1Infectious Disease Epidemiology Unit, London School of Hygiene and Tropical Background The US Centers for Disease Control and Prevention define syndromic surveillance as “an investigational approach where health department staff, assisted by automated data acquisition and generation of statistical ale
35.37 255 37.95 206 40.56 169 40.78 166 41.27 160 42.28 149 43.09 141 43.54 136 44.61 127 45.47 120 45.53 119 30.53 396 31.20 371 32.02 343 32.63 324 35.10 260 37.66 211 37.93 206 39.16 187 39.48 183 39.89 177 40.27 172 40.78 166 42.77 144 43.11 140 43.57 136 46.45 112 47.39 106 30.13 412 30.15 411 30.38 40